Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% – Time to Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) dropped 3.7% on Thursday . The company traded as low as $0.32 and last traded at $0.35. Approximately 51,497,243 shares were traded during trading, an increase of 103% from the average daily volume of 25,332,580 shares. The stock had previously closed at $0.36.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Sunday, December 15th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company’s 50 day moving average is $0.20 and its 200-day moving average is $0.49. The company has a market capitalization of $114.30 million, a P/E ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.